Bionure launches a crowdfunding campaign in Spain

Bionure has launched today a crowdfunding campaign through the Spanish platform of Capital Cell (capitalcel.es) with the objective of raising €1.3M that will be used to finance the preparation of the phase 2 study of its neuroprotectant BN201.

BN201 is a small molecule that has demonstrated neuroprotection and remyelination activity in several animal models of neurodegenerative diseases. It has successfully completed a clinical phase 1 study on the safety, tolerability and pharmacokinetics in single and multiple doses in healthy volunteers, under the approval of the MHRA, UK. It was backed by a Series A financing led by Alta Life Sciences. The company, whose prime focus areas are Acute Optic Neuritis (AON) and Multiple Sclerosis (MS), for which there are still high unmet medical needs. plans to start a phase 2 trial in early 2020.

The campaign #multiplesmotivos (multiple reasons) is part of a bridge round of €2.4M that will cover the expenses of regulatory and technical preparation of the phase 2 study.

More information (in Spanish) at multiplesmotivos.com.